Skip to content
Review Open access

Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strategies

Aug 2026 · Clinical and Translational Medicine · Vol 16 · 0 citations · 173 references
Medicine

TL;DR

Focusing on the disease characteristics of elderly AML, this narrative review summarizes the clinical efficacy of venetoclax, critically examines the multifaceted mechanisms of venetoclax resistance, and discusses current and emerging therapeutic strategies to overcome this resistance.

Abstract

Abstract To date, the treatment of acute myeloid leukaemia (AML) remains a major challenge in hematologic malignancies, particularly among elderly patients who are unfit for intensive chemotherapy. Venetoclax, a BCL‐2 inhibitor, in combination with azacitidine, has significantly improved the prognosis and survival of this patient population. However, approximately 30% of patients do not respond to venetoclax‐based combination regimens, and most initial responders eventually experience relapse. Therefore, resistance to venetoclax has become a critical bottleneck limiting its long‐term clinical benefits. A thorough understanding of the underlying resistance mechanisms and the development of novel strategies to overcome resistance are central to improving survival outcomes in elderly AML patients. The resistance mechanisms of venetoclax are complex and multifaceted, including genetic drivers such as TP53 mutations, FLT3‐ITD, and NRAS/KRAS mutations, as well as the upregulation of anti‐apoptotic proteins (e.g., MCL‐1, BCL‐xL), metabolic reprogramming, and altered cellular differentiation states. In response to these factors, emerging therapeutic strategies are rapidly evolving toward precision‐based and combination approaches, including combinations with targeted agents (e.g., IDH2 inhibitors, FLT3 inhibitors), MCL‐1 inhibitors, optimization of current dosing regimens (e.g., DEC3‐VEN), and the development of novel modalities (e.g., antibody‐drug conjugates, CAR‐T cell therapy). Focusing on the disease characteristics of elderly AML, this narrative review summarizes the clinical efficacy of venetoclax, critically examines the multifaceted mechanisms of venetoclax resistance, and discusses current and emerging therapeutic strategies to overcome this resistance. The goal is to inform clinical practice and guide future translational research. Key Points This review elucidates the current mechanism of action, therapeutic effects, and limitations of venetoclax, focusing on its use and combination regimens in the specific patient population of elderly individuals with AML who are not suitable for intensive therapy, as well as strategies to overcome resistance, and provides future perspectives for addressing venetoclax resistance.

Read PDF

Similar papers

Open access Oct 2026

Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis

ABSTRACT In recent years the addition of the oral BCL2 inhibitor venetoclax to hypomethylating agents (HMAs) has emerged as the standard‐of‐care for patients with acute myeloid leukemia (AML) who are not fit for intensive chemotherapy, significantly improving survival and quality‐of‐life. Venetoclax is metabolized main...

M. Sciumè, A. Bosi, A. Marchetti et al. · 0 citations
Open access Sep 2026

Azacitidine-Venetoclax in Elderly and Unfit Acute Myeloid Leukemia: Real-World Outcomes Outside Clinical Trials

Background: Azacitidine plus venetoclax (AZA+VEN) is the current standard first-line treatment for elderly or medically unfit patients with acute myeloid leukemia (AML). However, patients treated in real-world settings often differ from those enrolled in clinical trials due to frailty, comorbidities, secondary AML, and...

M. Fazio, D. Gerace, Giuseppe Mirabile et al. · 0 citations
Review Open access Oct 2026

Therapeutic strategies in the post-venetoclax era of acute myeloid leukemia

The therapeutic landscape of acute myeloid leukemia (AML) has changed substantially over the past decade with the incorporation of molecularly targeted agents, lower-intensity venetoclax-based regimens, and increasingly refined genetic risk stratification. Among these advances, the combination of venetoclax with hypome...

Huan Zhang, Shi-Jie Zhang, Jing-Xin Zhang · 0 citations
Clinical trial Sep 2026

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

BACKGROUND Induction chemotherapy has long been a key component of curative therapy for fit patients with acute myeloid leukemia (AML), despite its frequently severe side effects and substantial health care utilization. For patients who are ineligible for induction chemotherapy, hypomethylating therapy plus venetoclax...

Amir T. Fathi, Alexander E. Perl, Geoffrey Fell et al. · 3 citations
Open access Oct 2026

Venetoclax combined with olverembatinib and prednisone as a frontline therapeutic strategy for Philadelphia chromosome-positive mixed-phenotype acute leukemia

Mixed-phenotype acute leukemia (MPAL) is a rare hematological malignancy with poor prognosis, for which there are currently no standardized therapeutic guidelines. Preclinical and clinical studies have shown that venetoclax and BCR::ABL1 tyrosine kinase inhibitors have synergistic effects on Philadelphia chromosome–pos...

Xia Li, Yi-Le Zhou, Xiang-Jie Lin et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of risk-stratified chemotherapy with azacitidine for children with myeloid leukaemia with Down syndrome: protocol for a multicentre phase II trial (JCCG AML-D24)

Abstract Introduction The prognosis of myeloid leukaemia associated with Down syndrome (ML-DS) is excellent with reduced-intensity chemotherapy; however, that of refractory or relapsed ML-DS remains dismal. These contrasting outcomes highlight the importance of risk-stratified therapy, based on reliable prognostic fact...

Kentaro Nakashima, Daisuke Hasegawa, Jun Matsubayashi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.